No to {beta} agonists for tocolysis

doi:10.1136/bmj.b1502

Published 14 April 2009, doi:10.1136/bmj.b1502
Cite this as: BMJ 2009;338:b1502

Letters

Adverse reactions to tocolytics

No to β agonists for tocolysis

The first 100% of the full text of this article appears below.

That β agonists were still used for tocolysis in 2006-7,given their potentially serious side effects on maternal cardiovascularfunction, is surprising.¹ Indeed calcium channel blockers andatosiban are at least as effective as β agonists with fewersevere side effects.²

In addition, antenatal indomethacin, described as having nosevere maternal side effects,¹ may be associated with severeneonatal outcomes such as periventricular leukomalacia and necrotisingenterocolitis.³

Cite this as: BMJ 2009;338:b1502

Souhail Alouini, obstetrician and gynaecologist¹

¹ Centre Hospitalier Regional d’Orléans, 45000 Orleans, France

alouini.s@wanadoo.fr

Competing interests: None declared.

De Heus R, Mol BW, Erwich JJ, van Geijn HP, Gyselaers WJ, Hanssens M, et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ 2009;338:b744. (5 March.)[Abstract/Free Full Text]
Worldwide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. Br J Obstet Gynaecol 2001;108:133-42.[CrossRef][Web of Science]
Amin SB, Sinkin RA, Glantz JC. Meta-analysis of the effect of antenatal indomethacin on neonatal outcomes. Am J Obstet Gynecol 2007;197:486.e1-10.[Medline]

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

StumbleUpon Add to Technorati

Technorati What's this?

Relevant Article

Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study: Roel de Heus, Ben Willem Mol, Jan-Jaap H M Erwich, Herman P van Geijn, Wilfried J Gyselaers, Myriam Hanssens, Linda Härmark, Caroline D van Holsbeke, Johannes J Duvekot, Fred F A M Schobben, Hans Wolf, and Gerard H A Visser
BMJ 2009 338: b744. [Abstract] [Full Text] [PDF]